BiotechTube

Lipiodol Ultra Fluid with surgical glues

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Congenital Hemangioma

Conditions

Congenital Hemangioma, Hemangioendothelioma, Angiosarcoma, Arteriovenous Malformations

Trial Timeline

Nov 29, 2017 → May 12, 2021

NCT ID
NCT02625389

About Lipiodol Ultra Fluid with surgical glues

Lipiodol Ultra Fluid with surgical glues is a approved stage product being developed by Guerbet for Congenital Hemangioma. The current trial status is completed. This product is registered under clinical trial identifier NCT02625389. Target conditions include Congenital Hemangioma, Hemangioendothelioma, Angiosarcoma.

What happened to similar drugs?

4 of 20 similar drugs in Congenital Hemangioma were approved

Approved (4) Terminated (0) Active (16)
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
🔄turoctocog alfa pegolNovo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3
🔄vatreptacog alfa (activated) + eptacog alfa (activated)Novo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
✅turoctocog alfaNovo NordiskApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02625389ApprovedCompleted

Competing Products

20 competing products in Congenital Hemangioma

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
EDIT-101Editas MedicinePhase 1/2
18
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
KW-3357Kyowa KirinPhase 1
29
Pasireotide 0.6Mg Solution for Injection + Saline SolutionNovartisPhase 2
27
Sandostatine LPNovartisPhase 2
35
mycophenolate mofetilRochePhase 1
29
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
40
catridecacog + recombinant factor XIIINovo NordiskPhase 1
29
activated recombinant human factor VIINovo NordiskPhase 2
35
turoctocog alfa pegolNovo NordiskPhase 3
40
recombinant factor XIIINovo NordiskPre-clinical
26
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
29
Advate® + turoctocog alfaNovo NordiskPhase 1
29